Page 10 - Collaborative Group News Today

The findings could shine a light on the cause of the enduring, post-Covid condition - and help researchers develop new treatments to combat it.

Eli Lilly and Company and Boehringer Ingelheim announced the FDA approval of empagliflozin (Jardiance) for chronic kidney disease management on September 22, 2023.

SANTA MONICA - Kite, a Gilead Company , today announced results from the Phase 2 ALYCANTE study, led and sponsored by the French collaborative group LYSA/LYSARC, for use of its chimeric antigen...

– Yescarta Achieved a Complete Metabolic Response of 71% at 3 Months Versus 12% Expected with Historical Standard of Care Controls – – Results Published in Nature Medicine– ...

The substantial investments in human genetics and genomics made over the past three decades were anticipated to result in many innovative therapies. Here we investigate the extent to which these expectations have been met, excluding cancer treatments. In our search, we identified 40 germline genetic observations that led directly to new targets and subsequently to novel approved therapies for 36 rare and 4 common conditions. The median time between genetic target discovery and drug approval was ...

Researchers evaluated the impact of convalescent serum therapy on all-cause mortality among COVID-19 patients.

Researchers found young patients with chronic obstructive pulmonary disease (COPD) have a higher risk of all-cause mortality than those without COPD.

Treatment with adjuvant TAGRISSO reduced the risk of death by more than half ... | June 4, 2023

Treatment with adjuvant TAGRISSO reduced the risk of death by more than half Positive results from the ADAURA Phase III trial showed AstraZeneca's TAGRISSO (osimertinib) demonstrated a statistically

Heart Rhythm 2023, the society's 44th annual meeting, takes place May 19-21, in New Orleans